Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative

被引:26
作者
Cherng, SC
Huang, WH
Shiau, CY
Shiau, CY
Lee, AR
Chou, TC
机构
[1] Natl Def Med Ctr, Dept Physiol & Biophys, Taipei, Taiwan
[2] Tri Serv Gen Hosp, Dept Nucl Med, Taipei, Taiwan
[3] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
[4] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan
关键词
PC-09; platelet aggregation; cyclic AMP; thromboxane B-2; glycoprotein IIb/IIIa;
D O I
10.1016/j.ejphar.2005.12.022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, we examined whether PC-09, a new pyridazinone derivative, has antiplatelet activity in vitro and further investigated the possible mechanisms involved. Pretreatment with PC-09 resulted in an inhibition on rabbit platelet aggregation and ATP release induced by arachidonic acid, collagen or thrombin, with the IC50 values of 5.4 to 76.8 mu M. The thromboxane B, formation caused by collagen or thrombin was markedly inhibited by PC-09, but there was no alteration in that caused by arachidonic acid. The rise of platelet intracellular calcium level stimulated by aggregation agonists and collagen-induced platelet membrane surface glycoprotein IIb/IIIa expression was also reduced by PC-09. In addition, PC-09 itself significantly increased the cyclic AMP level through inhibiting cyclic AMP phosphodiesterase activity. These findings demonstrate that PC-09 is an inhibitor of platelet aggregation, which may be associated with mechanisms including inhibition of thromboxane A, formation, intracellular calcium mobilization and platelet surface GPIIb/IIIa expression accompanied by increasing cyclic AMP level. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 25 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]  
BELL RL, 1979, P NATL ACAD SCI USA, V76, P1790
[3]  
BILLAH MM, 1981, J BIOL CHEM, V256, P5399
[4]   Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro [J].
Buerke, M ;
Cyrus, T ;
Darius, H .
THROMBOSIS RESEARCH, 1997, 88 (02) :89-98
[5]  
Chou TC, 1998, ANESTH ANALG, V86, P1065
[6]   Chitosan enhances platelet adhesion and aggregation [J].
Chou, TC ;
Fu, E ;
Wu, CJ ;
Yeh, JH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 302 (03) :480-483
[7]   Inhibitory mechanisms of dantrolene on platelet aggregation [J].
Chou, TC ;
Li, CY .
THROMBOSIS RESEARCH, 1999, 96 (04) :299-307
[8]   A NOVEL ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PLA2 CONTAINS A CA2+-DEPENDENT TRANSLOCATION DOMAIN WITH HOMOLOGY TO PKC AND GAP [J].
CLARK, JD ;
LIN, LL ;
KRIZ, RW ;
RAMESHA, CS ;
SULTZMAN, LA ;
LIN, AY ;
MILONA, N ;
KNOPF, JL .
CELL, 1991, 65 (06) :1043-1051
[9]  
Dogné JM, 2001, CARDIOVASC DRUG REV, V19, P87
[10]   RELATIONSHIP BETWEEN CAMP AND CA-2+ FLUXES IN HUMAN-PLATELET MEMBRANES [J].
ENOUF, J ;
BREDOUX, R ;
BOURDEAU, N ;
GIRAUD, F ;
LEPEUCH, C ;
LEBRET, M ;
LEVYTOLEDANO, S .
BIOCHIMIE, 1987, 69 (04) :297-304